Therapeutic advances in anaplastic thyroid cancer: a current perspective.
Therapeutic advances in anaplastic thyroid cancer: a current perspective.
复制标题
DOI：
10.1186/s12943-018-0903-0
复制
发表时间：
2018-10-23
期刊：
影响因子：
37.3
通讯作者：
Prabhakar BS
中科院分区：
文献类型：
--
作者：
Saini S;Tulla K;Maker AV;Burman KD;Prabhakar BS
甲状腺癌的发病率正以惊人的速度增长，几乎每十年增加三倍。2017年，它是女性第五大常见癌症。虽然大多数甲状腺肿瘤是可治愈的，但约2-3%的甲状腺癌是标准治疗难以治愈的。这些未分化的、高度侵袭性的和大多数化学抗性的肿瘤在表型上被称为间变性甲状腺癌（ATC）。ATC对标准疗法具有抗性，并且极难管理。在这篇综述中，我们提供了与当前和最近出现的一线全身治疗（达拉非尼和曲美替尼）相关的信息，沿着有前途的治疗方法正在进行临床试验，并可能在未来纳入临床实践。不同类别的有前途的治疗，如极光激酶抑制剂，多激酶抑制剂，表观遗传调节剂，使用溶瘤病毒的基因治疗，肿瘤诱导剂和免疫治疗进行了综述。还讨论了显示协同和拮抗作用的联合治疗方案。我们强调正在进行的临床试验在ATC和讨论如何个性化医疗是至关重要的设计二线治疗。除了使用传统的联合治疗外，采用基于先进基因组学和蛋白质组学评估的个性化方法对于制定量身定制的治疗计划以提高临床成功的机会至关重要。
Thyroid cancer incidence is increasing at an alarming rate, almost tripling every decade. In 2017, it was the fifth most common cancer in women. Although the majority of thyroid tumors are curable, about 2–3% of thyroid cancers are refractory to standard treatments. These undifferentiated, highly aggressive and mostly chemo-resistant tumors are phenotypically-termed anaplastic thyroid cancer (ATC). ATCs are resistant to standard therapies and are extremely difficult to manage. In this review, we provide the information related to current and recently emerged first-line systemic therapy (Dabrafenib and Trametinib) along with promising therapeutics which are in clinical trials and may be incorporated into clinical practice in the future. Different categories of promising therapeutics such as Aurora kinase inhibitors, multi-kinase inhibitors, epigenetic modulators, gene therapy using oncolytic viruses, apoptosis-inducing agents, and immunotherapy are reviewed. Combination treatment options that showed synergistic and antagonistic effects are also discussed. We highlight ongoing clinical trials in ATC and discuss how personalized medicine is crucial to design the second line of treatment. Besides using conventional combination therapy, embracing a personalized approach based on advanced genomics and proteomics assessment will be crucial to developing a tailored treatment plan to improve the chances of clinical success.
登录
查看更多内容
影响因子：
3.7
作者：
Caillou B;Talbot M;Weyemi U;Pioche-Durieu C;Al Ghuzlan A;Bidart JM;Chouaib S;Schlumberger M;Dupuy C
通讯作者：
Dupuy C
影响因子：
3.7
作者：
Chin LH;Hsu SP;Zhong WB;Liang YC
通讯作者：
Liang YC
影响因子：
8
作者：
Borbone, E.;Berlingieri, M. T.;Fusco, A.
通讯作者：
Fusco, A.
影响因子：
--
作者：
Brauner E;Gunda V;Vanden Borre P;Zurakowski D;Kim YS;Dennett KV;Amin S;Freeman GJ;Parangi S
通讯作者：
Parangi S
DOI：
10.1158/1078-0432.ccr-15-2792
发表时间：
2016-12-15
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Abdulghani J;Gokare P;Gallant JN;Dicker D;Whitcomb T;Cooper T;Liao J;Derr J;Liu J;Goldenberg D;Finnberg NK;El-Deiry WS
通讯作者：
El-Deiry WS